Cellestia is giving hope to cancer patients who have no other treatment or therapy options. Our drug discovery platform, built on a unique mode of action and together with companion diagnostics, is a first-in-class solution for orphan cancers such as cancer of the salivary gland and childhood Leukaemia. At the same time, we are continuing to expand our portfolio through targeting large cancer indications such as breast and colorectal cancers.
Cellestia is a privately-owned clinical-stage biopharma company led by an experienced team of scientists, drug developers and business professionals. We are providing hope for thousands of cancer patients and their families.
cure

WE ASPIRE TO

Cure cancer

We aspire to reach true breakthroughs in cancer treatments and therapies that will ultimately lead to a cure for cancers previously incurable.

patients

WE ARE RESOLUTE IN OUR

Dedication to patients

There is no compromise to our dedication to the patients we serve. We put their needs first and are resolute in our search for groundbreaking novel therapies.
health

WE EXTEND AND IMPROVE

Quality of life

We are developing safe and therapeutic solutions to extend and improve the quality of life for patients who currently have no other treatment options.
pioneering

WE ARE RELENTLESS IN OUR PURSUIT OF

Pioneering science

While others may use words like innovative, unique and novel in an attempt to differentiate themselves, CB-103’s mode of action is a true scientific disruption in the treatment of NOTCH-driven cancers.
futur

WE DO WHATEVER IT TAKEs TO

Adapt to the unknown and shape
the future

We hold each other responsible and accountable to the vision and goals we share as we carve our own path forward.

all_in

We are all in

We understand what is at stake for patients and their families and as a result we are willing to put our reputations, time with our loved ones and our own resources on the line. We are all in.

History

2012

First patent application filed.

2015

Michael Bauer joins, the Management Team is extended,
and the HQ move to Basel.

2017

First patient treated in December.

2019

Safety and Efficacy Data available.

adn

2008

Project starts with Raj Lehal’s doctoral thesis.

2014

Cellestia is founded in Lausanne by Prof. Freddy Radtke
and Raj Lehal.

2016

CB-103 development begins.

2018

CHF 29 m raised in private equity.

2020

Planning start of Ph ll Clinical Program.

History

2008

Project starts with Raj Lehal’s doctoral thesis.

2012

First patent application filed.

2014

Cellestia is founded in Lausanne by Prof. Freddy Radke and Raj Lehal.

2015

Michael Bauer joins, the Management Team is extended, and the HQ move to Basel.

2016

CB-103 development begins.

2017

First patient treated in December.

2018

CHF 29 m raised in private equity.

2019

Safety and Efficacy Data available.

2020

Planning start of Ph ll Clinical Program.

RAJ’S STORY

If my research can make a difference for even one single cancer patient, I would consider this the reward of my lifetime.

Partners & Collaboration
Research

Adenoid Cystic Carcinoma Research Foundation
University of Cincinnati
EPFL
IOR - Institute of Oncology Research
Universitats Kinderspital Zurich
MD Anderson Cancer Network
Swiss Institute of Bioinformatics
Universitatsklinikum Schleswig-Holstein
VHIO
The Christie NHS Foundation Trust
Harvrad Medical School
Penn - Univesity of Pennsylvania
LSU Health - New Orleans
Unil - Université de Lausanne
Brigham Health - Brigham and Women's Hospital

Partners & Collaboration
Clinics

VHIO
EOC
MD Anderson Cancer Network
IOB Quironsalud
Institute of Hermatology & Bmppd Diseases Hospital
Hospital Universitario Ramon y Cajal

Partners & Collaboration
Business

Venture Leaders
TechnologyParkBasel
Schweizerische Eidgenossenschaft
Innovaud
Canton de Vaud
Biopole